

September 19, 2022

RE: EudraCT number: 2020-005936-31

Sponsor Code: SMX18-001

Title: An Open-label, Randomized, Multicenter Study Evaluating the Activity of Lasofoxifene Relative to Fulvestrant for the Treatment of Pre- and Postmenopausal Women with Locally Advanced or Metastatic ER+/HER2- Breast Cancer with an ESR1 Mutation

This letter is being sent to clarify why the trial was prematurely ended in Lithuania and to confirm there are no results to report. Our trial was initiated at sites in Lithuania towards the end of the recruitment period. Sites in the US, Canada and Israel were initiated much earlier and full enrollment was achieved prior to any screening activity in Lithuania. The study achieved full recruitment in September 2021 and results from the trial were recently presented at ESMO September 10, 2022.

If you have any questions, please contact me at 614-324-0563 EXT 202 or email mportman@sermonixpharma.com

Kind regards,

Miriam Portman

Miriam Portman

Chief Operating Officer